CEACAM5 and lung adenocarcinoma: Therefore, to test whether EGFR-TKI treatment affects CEA expression pattern and dissemination ability of lung cancer cells harboring EGFR mutations, we treated EGFR-mutant HCC827 (delE746_A750) lung adenocarcinoma cells with increasing concentrations of gefitinib.